Amifampridine overdose leading to refractory status epilepticus - Gooley B, Willenbring B, Wilkinson J.
3,4-Aminopyridine or Amifampridine belongs to the aminopyridine class of drugs which is used to treat multiple sclerosis and Lambert-Eaton Myasthenic Syndrome (LEMS). Aminopyridine pharmaceuticals inhibit presynaptic potassium channels. This increases avai... (Source: SafetyLit)
Source: SafetyLit - May 6, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Myasthenia Gravis: Advice for the Generalist Myasthenia Gravis: Advice for the Generalist
Neurologists Kathrin LaFaver and Kim Robeson-Gewuerz discuss what tests and treatments you should consider when myasthenia gravis is suspected.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 3, 2024 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

Myasthenia Gravis in Pregnancy and the Newborn
(Source: NeoReviews recent issues)
Source: NeoReviews recent issues - April 1, 2024 Category: Pediatrics Source Type: news

Promising Results for Investigational Myasthenia Gravis Drug Promising Results for Investigational Myasthenia Gravis Drug
Treatment with batoclimab resulted in a nearly 60% sustained improvement in daily activities in adult patients with generalized myasthenia gravis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 13, 2024 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery Source Type: news

Investigational Agent Shows Benefit in Myasthenia Gravis
(MedPage Today) -- The investigational monoclonal antibody batoclimab led to significant improvement in activities of daily living in people with generalized myasthenia gravis (gMG), a multicenter phase III trial found. The rate of sustained improvement... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - March 6, 2024 Category: Neurology Source Type: news

Promising Phase 2 Results for Myasthenia Gravis Med Promising Phase 2 Results for Myasthenia Gravis Med
Intravenous nipocalimab provides clinical benefits for patients with generalized myasthenia gravis, an IgG autoantibody-mediated disease characterized by muscle weakness.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - January 9, 2024 Category: Internal Medicine Tags: Neurology & Neurosurgery Source Type: news

Advice That Helps and Advice That Hurts When You Have Myasthenia Gravis
A patient living with myasthenia gravis talks about the most helpful – and hurtful – advice she has received since her diagnosis. (Source: WebMD Health)
Source: WebMD Health - January 2, 2024 Category: Consumer Health News Source Type: news

What I ’ve Learned About the Challenges of MG
A doctor who regularly treats myasthenia gravis patients details what he has learned from them and how he applies those lessons to his own life. (Source: WebMD Health)
Source: WebMD Health - January 2, 2024 Category: Consumer Health News Source Type: news

Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna's KYSA-6 Phase 2 open-label, multicenter study KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EM... Biopharmaceuticals, FDA Kyverna Therapeutics, chimeric antigen receptor, Myasthenia Gravis, autoimmune (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2023 Category: Pharmaceuticals Source Type: news

Novel Myasthenia Gravis Therapies Bring Opportunities Novel Myasthenia Gravis Therapies Bring Opportunities
New treatments for myasthenia gravis are bringing new promise to patients, but their use must be balanced against short-term and long-term risks.MDedge News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 27, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Myasthenia Gravis Highlights From AANEM 2023 Myasthenia Gravis Highlights From AANEM 2023
Key data on myasthenia gravis from AANEM 2023 include results on the ADAPT+ study of efgartigimod, inequities in diagnosis, and eculizumab use in pregnancy, as reviewed by Dr Nicholas Silvestri.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news

Myasthenia Gravis: new drugs and a road to individualized treatment
What you need to know about the complex autoimmune disease that interferes with the communication between nerves and muscles. (Source: Yale Science and Health News)
Source: Yale Science and Health News - November 20, 2023 Category: Universities & Medical Training Source Type: news

Sustained Benefit for Newly Approved Myasthenia Gravis Drug Sustained Benefit for Newly Approved Myasthenia Gravis Drug
Early responders to zilucoplan, the newly approved medication for myasthenia gravis have sustained benefit for up to 60 weeks, new analyses show.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 14, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

In Myasthenia Gravis, Antibodies Pass Open-Label Tests In Myasthenia Gravis, Antibodies Pass Open-Label Tests
Researchers presented data from an open-label extension study following the phase 3 MycarinG trial of rozanolixizumab and the ADAPT-SC+ study of efgartigimod.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 3, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

In Myasthenia Gravis, Antibodies Pass Open-Label Tests In Myasthenia Gravis, Antibodies Pass Open-Label Tests
Researchers presented data from an open-label extension study following the phase 3 MycarinG trial of rozanolixizumab and the ADAPT-SC+ study of efgartigimod.MDedge News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 3, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news